Le vaccin antipaludique RTS, S/AS01 chez les enfants âgés de 5 à 17 mois au moment de la première vaccination
P Vandoolaeghe, L Schuerman - Pan African Medical Journal, 2018 - ajol.info
Le vaccin antipaludique RTS, S/AS01 a reçu un avis scientifique favorable de l'Agence
Européenne des Médicaments (EMA) en juillet 2015. L'Organisation Mondiale de la Santé …
Européenne des Médicaments (EMA) en juillet 2015. L'Organisation Mondiale de la Santé …
The RTS, S/AS01 malaria vaccine in children aged 5-17 months at first vaccination
P Vandoolaeghe, L Schuerman - The Pan African Medical Journal, 2018 - europepmc.org
Résumé Le vaccin antipaludique RTS, S/AS01 a reçu un avis scientifique favorable de
l'Agence Européenne des Médicaments (EMA) en Juillet 2015. L'Organisation Mondiale de …
l'Agence Européenne des Médicaments (EMA) en Juillet 2015. L'Organisation Mondiale de …
Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 …
RTS, S Clinical Trials Partnership (2014) - PLoS medicine, 2014 - journals.plos.org
Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …
Long-term incidence of severe malaria following RTS, S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 …
Background Results from a previous phase 3 study showed efficacy of the RTS, S/AS01
vaccine against severe and clinical malaria in children (in 11 sites in Africa) during a 3–4 …
vaccine against severe and clinical malaria in children (in 11 sites in Africa) during a 3–4 …
Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial
Background Development of an effective malaria vaccine could greatly contribute to disease
control. RTS, S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium …
control. RTS, S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium …
Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial
JJ Aponte, P Aide, M Renom, I Mandomando, Q Bassat… - The Lancet, 2007 - thelancet.com
Background Malaria remains a leading global health problem that requires the improved
use of existing interventions and the accelerated development of new control methods. We …
use of existing interventions and the accelerated development of new control methods. We …
[HTML][HTML] Safety and immunogenicity of the RTS, S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan …
L Otieno, YG Mendoza, S Adjei, T Agbenyega… - Vaccine, 2020 - Elsevier
Background We assessed the safety and immunogenicity of the RTS, S/AS01 malaria
vaccine in a subset of children identified as HIV-infected during a large phase III randomized …
vaccine in a subset of children identified as HIV-infected during a large phase III randomized …
[PDF][PDF] RTS, S/AS01 malaria vaccine in African children
AV Hill - N Engl J Med, 2012 - core.ac.uk
To the Editor: In the article by the RTS, S Clinical Trials Partnership (Nov. 17 issue) 1 on the
phase 3 trial of RTS, S (ClinicalTrials. gov number, NCT00866619), an analysis of the …
phase 3 trial of RTS, S (ClinicalTrials. gov number, NCT00866619), an analysis of the …
Design of a phase III multicenter trial to evaluate the efficacy of the RTS, S/AS01 malaria vaccine in children across diverse transmission settings in Africa
A Leach, J Vekemans, M Lievens, O Ofori-Anyinam… - Malaria journal, 2011 - Springer
Abstract Background GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative
are working in partnership to develop a malaria vaccine to protect infants and children living …
are working in partnership to develop a malaria vaccine to protect infants and children living …
Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised …
S Rts - Lancet, 2015 - thelancet.com
Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …
18 months of follow-up have been published previously. Herein, we report the final results …